Clinical Trial Update: SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating SBRT plus lenvatinib and TACE for advanced hepatocellular carcinoma is in the NOT_YET_RECRUITING stage.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• SBRT (stereotactic body radiotherapy)
• TACE

Snippet

Sponsor: Sun Yat-sen University | Conditions: Advanced Hepatocellular Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING